0001759655-21-000033.txt : 20211108 0001759655-21-000033.hdr.sgml : 20211108 20211108063932 ACCESSION NUMBER: 0001759655-21-000033 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Privia Health Group, Inc. CENTRAL INDEX KEY: 0001759655 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40365 FILM NUMBER: 211386453 BUSINESS ADDRESS: STREET 1: 950 N. GLEBE RD., SUITE 700 CITY: ARLINGTON STATE: VA ZIP: 22203 BUSINESS PHONE: 571-366-8850 MAIL ADDRESS: STREET 1: 950 N. GLEBE RD., SUITE 700 CITY: ARLINGTON STATE: VA ZIP: 22203 FORMER COMPANY: FORMER CONFORMED NAME: PH Group Parent Corp. DATE OF NAME CHANGE: 20181120 8-K 1 prva-20211108.htm 8-K prva-20211108
0001759655FALSE00017596552021-11-082021-11-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2021
_________________________
Privia Health Group, Inc.
(Exact Name of Registrant as Specified in Its Charter)
_________________________
Delaware
001-4036581-3599420
(State or other jurisdiction of incorporation or organization)
(Commission
File No.)
(I.R.S. Employer Identification No.)
950 N. Glebe Rd.,
Suite 700
Arlington,Virginia22203
(Address of Principal Executive Offices)
(Zip Code)
(571) 366-8850
Registrant's telephone number, including area code

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02 Results of Operations and Financial Condition.

On November 8, 2021, Privia Health Group, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2021. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit:
Exhibit No.Description
99.1
Privia Health Group, Inc. Press Release Dated November 8, 2021



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRIVIA HEALTH GROUP, INC.
Date: November 8, 2021
By:/s/ David Mountcastle
Name: David Mountcastle
Title: Chief Financial Officer and Authorized Officer



EXHIBIT INDEX

EX-99.1 2 ex-9913q21earningrelease.htm EX-99.1 Document
privialogoa.jpg
Exhibit 99.1

Privia Health Reports Third Quarter 2021 Financial Results

Raises Full-Year 2021 Guidance on All Metrics
Record New Provider Growth
Strong Performance in 2020 MSSP and Other Value-based Programs
Entry into California and West Texas Markets to Accelerate Growth

ARLINGTON, VA – November 8, 2021 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the third quarter and nine-month periods ended September 30, 2021.
Third Quarter
Total revenue for the third quarter of 2021 was $251.5 million, compared to total revenue of $207.2 million for the prior year third quarter (+21.4%). Operating loss for the third quarter of 2021 was $12.8 million, compared to operating income of $8.5 million for the prior year third quarter. Net loss for the third quarter of 2021 was $9.1 million, or a loss of $0.09 per share, compared to net income of $16.7 million, or $0.17 per share, for the third quarter of 2020. Net loss for the third quarter of 2021 included $25.8 million in non-cash stock compensation expense and $0.4 million in other non-recurring expenses.
Non-GAAP adjusted net income was $15.0 million, or $0.13 per diluted share, for the third quarter of 2021, compared to $8.4 million, or $0.09 per diluted share, for the prior year third quarter (+78.8%).
Reconciliation of net (loss) income to adjusted net income, as well as other non-GAAP reconciliations, are presented in tables near the end of this press release.
Key operating and non-GAAP financial metrics include:
Practice Collections for the third quarter of 2021 were $401.5 million, compared to $339.9 million for the same period in 2020 (+18.1%).
Care Margin for the third quarter of 2021 was $61.5 million, compared to $46.7 million for the same period in 2020 (+31.5%).
Platform Contribution for the third quarter of 2021 was $31.1 million, compared to $21.5 million for the same period in 2020 (+44.7%).
Adjusted EBITDA for the third quarter of 2021 was $13.9 million, compared to $9.1 million for the same period in 2020 (+51.9%).
Implemented Providers for the third quarter of 2021 were 2,826, compared to 2,454 at the end of the third quarter of 2020 (+15.2%).
Value-Based Care Attributed Lives for the third quarter of 2021 were approximately 760,000, compared to 646,000 at the end of the third quarter of 2020 (+17.6%).
“We delivered another quarter of strong growth, with practice collections in the third quarter increasing 18.1%, care margin growing 31.5% and adjusted EBITDA up 51.9% when compared to the third quarter last year,” said Shawn Morris, Chief Executive Officer, Privia Health. “We continue to gain momentum with greater awareness of our uniquely aligned provider partnership model, which is highlighted by 15.2% growth of implemented providers and a 17.6% increase in attributed lives across a number of value-based reimbursement programs from a year ago.
“As we noted last quarter, we continued to expand our number of provider partners, increase attributed lives, enter new markets and leverage our capital-efficient operating structure,” Morris added. “We
1


expect to accelerate top-line growth and continue to expand our profit margin as we execute on our multiple market opportunities in the coming year.”
Nine Months
Total revenue for the first nine months of 2021 was $690.9 million, compared to total revenue of $603.4 million for the same period in the prior year (+14.5%). Operating loss for the first nine months of 2021 was $198.1 million, compared to operating income of $21.2 million for the same period in the prior year. Net loss for the first nine months of 2021 was $176.3 million, or a loss of $1.74 per share, compared to net income of $27.4 million, or $0.29 per share, for the same period in 2020. Net loss for the first nine months of 2021 included $228.5 million in non-cash stock compensation expense and $2.1 million in other non-recurring expenses.
Non-GAAP adjusted net income was $34.6 million or $0.31 per diluted share, compared to $21.1 million, or $0.22 per diluted share, for the same period in the prior year (+64.2%).
Practice Collections for the first nine months of 2021 were $1.11 billion, compared to $949.0 million for the same period in the prior year (+17.3%). Care Margin was $169.8 million, compared to $136.3 million for the nine months ended in September 30, 2020 (+24.5%). Platform Contribution for the first nine months of 2021 was $79.8 million, compared to $59.2 million for the same period in the prior year (+34.8%). Adjusted EBITDA was $33.9 million, compared to $23.2 million for the nine months ended in September 30, 2020 (+45.9%).
Value-Based Shared Savings Performance
On August 25, 2021, Privia Health announced its Accountable Care Organizations (ACOs) delivered quality care and improved patient outcomes, and achieved shared savings of $86.5 million through the Medicare Shared Savings Program (MSSP). The Company’s ACOs, collectively the Privia Quality Network, include physicians and advanced practitioners in Georgia, Maryland, Texas, Virginia and Washington, DC, who provided high-value, cost-efficient care to over 121,000 Medicare beneficiaries in 2020.
Across the Privia Quality Network, the ACOs lowered inpatient and outpatient facility spend as well as emergency room utilization, among other positive performance metrics, when compared to the median MSSP ACO and total fee-for-service Medicare. Since 2014, the Company’s ACOs have realized total shared savings across government programs and commercial payers of more than $576 million, including over $281 million through participation in the MSSP.
New Market Entries
On October 18, 2021, Privia Health announced its entrance into the California market through an affiliation with BASS Medical Group, one of the Greater San Francisco Bay Area’s leading healthcare multi-specialty groups with more than 400 providers spanning 42 specialties caring for patients at over 125 locations. The Company also launched Privia Medical Group – West Texas with anchor partner Abilene Diagnostic Clinic, an independent multi-specialty group practice with more than 30 providers and five care center locations. This expands Privia Health’s presence in Texas, complements its established and expanding provider practice locations in North Texas and Gulf Coast regions, and will take advantage of economies of scale across the state.
These new partnerships demonstrate Privia Health’s ability to replicate its operating model with new medical groups in uniquely differentiated markets as the Company executes on its vision to build scaled provider networks nationwide and enable providers to transition profitably to increased risk in value-based programs over time.
2


Financial and Business Outlook a b
Privia Health is updating its full-year 2021 guidance to reflect management’s expectation of the fourth quarter impact of the Company’s recent entry into the California and West Texas markets as well as its strong year-to-date performance and positive business momentum in existing markets, as follows:

Initial FY 2021 Guidance 5.27.21Guidance at 8.9.21Current FY 2021 Guidance 11.8.21
($ in millions)LowHighLowHigh
Implemented Providers2,850 2,900 Mid-to-High End3,300 3,330 
Attributed Lives730,000 750,000 High End760,000 765,000 
Practice Collections$ 1,445$ 1,465High End$ 1,520$ 1,540
GAAP Revenue860880High End900920
Care Margin215221High End225230
Platform Contribution9398High End102105
Adjusted EBITDA c
$ 34$ 38High End$ 39$ 41
a.Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of operating income and net income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.
b.See “Key Metrics and Non-GAAP Financial Measures” for more information as to how the Company defines and calculates Implemented Providers, Attributed Lives, Practice Collections, Care Margin, Platform Contribution, and Adjusted EBITDA, and for a reconciliation of the most comparable GAAP measures to Care Margin, Platform Contribution, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Per Share.
Certain non-recurring or non-cash expenses will be treated as an add back in the reconciliation of Net Income to Adjusted EBITDA, and the reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share, the details of which can be found in the Reconciliation schedules near the end of this and in future quarterly financial press releases.
c.Adjusted EBITDA guidance does not add back actual or estimated new market entry and development costs.
3


Webcast and Conference Call Information
The Company will host a conference call on November 8, 2021, at 8:00 am ET / 7:00 am CT to discuss these results and management’s outlook for future financial and operational performance. The conference call can be accessed via webcast at ir.priviahealth.com/news-and-events/events-and-presentations or by dialing 855-940-5315 (929-517-0419 for international participants), and referencing participant code 4491575.
The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call at ir.priviahealth.com/news-and-events/events-and-presentations. This news release and the financial statements contained herein, and the slide presentation for the webcast, are also available on the Privia Health Investor Relations website at ir.priviahealth.com.
About Privia Health
Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. Our platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.
Non-GAAP Financial Measures
The Company reports and discusses its operating results using financial measures consistent with accounting principles generally accepted in the United States ("GAAP"). From time to time, in press releases, financial presentations, earnings conference calls or otherwise, the Company may disclose certain non-GAAP financial measures. The non-GAAP financial measures presented in this press release should not be viewed as alternatives or substitutes for the Company's reported GAAP results. A reconciliation to the most directly comparable GAAP financial measure is set forth in the tables that accompany this release.
The Company believes that the non-GAAP financial measures presented in this press release are relevant and provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because the measures allow them to understand and compare the Company's actual and expected operating results during the prior, current and future periods in a more consistent manner. The non-GAAP measures presented in this press release may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provides a more complete understanding of the results of operations and trends affecting the Company's business. These non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to financial measures calculated in accordance with GAAP.

4


Safe Harbor Statement
The financial results in this press release reflect preliminary, unaudited results, which are not final until the Company’s Form 10-Q is filed with the Securities and Exchange Commission (“SEC”). This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” "assumes," “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things, the possible effects of COVID-19; our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full year guidance for 2021. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements.
Factors related to these risks and uncertainties include, but are not limited to: compliance with applicable healthcare laws and government regulations in the heavily regulated industry in which the Company operates; the Company’s dependence on relationships with its medical groups, some of which the Company does not own; the Company’s growth strategy, which may not prove viable and the Company may not realize expected results; difficulties implementing the Company’s proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups; the high level of competition in the Company’s industry and the Company’s failure to compete and innovate; challenges in successfully establishing a presence in new geographic markets; the Company’s reliance on its electronic medical record vendor, which the Privia Technology Solution is integrated and built upon; changes in the payer mix of patients and potential decreases in the Company’s reimbursement rates as a result of consolidation among commercial payers; the Company’s use, disclosure, and other processing of personally identifiable information, including health information, is subject to the Health Insurance Portability and Accountability Act of 1996 and other federal and state privacy and security regulations; and those factors referenced in Part II, Item 1A, “Risk Factors” in the Company’s final prospectus dated April 28, 2021, filed with the SEC on April 30, 2021, and the Company’s other public filings.

Contact:
Robert Borchert
SVP, Investor & Corporate Communications
IR@priviahealth.com
817.783.4841




5


Privia Health Group, Inc.
Condensed Consolidated Statements of Operations (a)
Unaudited
(in thousands, except share and per share data)

For the Three Months Ended September 30,For the Nine Months Ended September 30,
2021202020212020
Revenue$251,524 $207,170 $690,887 $603,376 
Operating expenses:
Physician and practice expense190,055 160,432 521,105 467,059 
Cost of platform35,314 25,241 131,007 77,133 
Sales and marketing4,588 2,709 18,950 7,381 
General and administrative33,910 9,788 216,563 29,196 
Depreciation and amortization466 457 1,351 1,389 
Total operating expenses264,333 198,627 888,976 582,158 
Operating (loss) income(12,809)8,543 (198,089)21,218 
Interest expense292 504 885 1,480 
(Loss) income before benefit from income taxes(13,101)8,039 (198,974)19,738 
Benefit from income taxes(2,210)(8,561)(20,214)(7,387)
Net (loss) income(10,891)16,600 (178,760)27,125 
Less: Loss attributable to non-controlling interests(1,776)(85)(2,509)(255)
Net (loss) income attributable to Privia Health Group, Inc. $(9,115)$16,685 $(176,251)$27,380 
Net (loss) income per share attributable to Privia Health Group, Inc. stockholders – basic and diluted$(0.09)$0.17 $(1.74)$0.29 
Weighted average common shares outstanding – basic and diluted105,896,622 95,950,929 101,576,775 95,945,804 
(a) Any slight variations in totals due to rounding.

6


Privia Health Group, Inc.
Condensed Consolidated Balance Sheets(a)
(in thousands)
September 30, 2021December 31, 2020
Assets(unaudited)
Current assets:
Cash and cash equivalents$362,112 $84,633 
Accounts receivable98,384 99,118 
Prepaid expenses and other current assets8,928 6,333 
Total current assets469,424 190,084 
Non-current assets:
Property and equipment, net4,341 4,814 
Right-of-use asset5,377 — 
Intangible assets, net5,498 5,980 
Goodwill118,663 118,663 
Deferred tax asset25,374 4,953 
Other non-current assets3,384 4,475 
Total non-current assets162,637 138,885 
Total assets$632,061 $328,969 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$3,266 $5,235 
Accrued expenses31,303 31,185 
Physician and practice liability144,996 106,811 
Current portion of note payable875 875 
Operating lease liabilities, current2,200 — 
Other current liabilities4,602 2,832 
Total current liabilities187,242 146,938 
Non-current liabilities:
Note payable, net of current portion31,664 32,784 
Operating lease liabilities, non-current7,827 — 
Other non-current liabilities333 5,595 
Total non-current liabilities39,824 38,379 
Total liabilities227,066 185,317 
Commitments and contingencies
Stockholders’ equity:
Common stock 1,062 960 
Additional paid-in capital605,667 165,666 
Accumulated deficit(196,129)(19,878)
Total Privia Health Group, Inc. stockholders’ equity410,600 146,748 
Non-controlling interest(5,605)(3,096)
Total stockholders’ equity404,995 143,652 
Total liabilities and stockholders’ equity$632,061 $328,969 
(a) Any slight variations in totals are due to rounding.

7


Privia Health Group, Inc.
Consolidated Statements of Cash Flows (a)
unaudited
(In thousands)For the Nine Months Ended September 30,
20212020
Cash flows from operating activities
Net (loss) income$(178,760)$27,125 
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation 869 895 
Amortization of intangibles482 483 
Amortization of debt issuance costs120 100 
Stock-based compensation228,461 363 
Deferred tax benefit(20,421)(7,770)
Changes in asset and liabilities:
Accounts receivable734 (10,138)
Prepaid expenses and other current assets(7,972)(1,570)
Other non-current assets1,091 2,242 
Accounts payable(2,064)2,459 
Accrued expenses118 (4,061)
Physician and practice liability38,185 30,883 
Other current liabilities1,770 815 
Operating lease liabilities10,027 — 
Other long-term liabilities(5,262)404 
Net cash provided by in operating activities67,378 42,230 
Cash from investing activities
Purchases of property and equipment(396)(380)
Net cash used in investing activities(396)(380)
Cash flows from financing activities
Proceeds from initial public offering223,686 — 
Payments of underwriting fees, net of discounts and offering costs(12,691)— 
Repayment of note payable (656)(656)
Proceeds from exercised stock options648 108 
Debt issuance costs(490)— 
Proceeds from revolving loan— 10,000 
Line of credit payments— (10,000)
Net cash provided by (used in) financing activities210,497 (548)
Net increase in cash and cash equivalents277,479 41,302 
Cash and cash equivalents at beginning of period84,633 46,889 
Cash and cash equivalents at end of period$362,112 $88,191 
Supplemental disclosure of cash flow information:
Interest paid$855 $1,599 
Income taxes paid$451 $371 
(a) Any slight variations in totals are due to rounding.
8



Key Metrics and Non-GAAP Financial Measures

Privia Health reviews a number of operating and financial metrics, including the following key metrics and non-GAAP financial measures, to evaluate the Company’s business, measure performance, identify trends affecting the Company’s business, formulate business plans, and make strategic decisions.

Key Metrics(a)
For the Three Months Ended September 30,For the Nine Months Ended September 30,
(unaudited; $ in millions)2021202020212020
Implemented Providers (as of end of period) (1)
2,826 2,454 2,826 2,454 
Attributed Lives (as of end of period) (2)
760,000 646,000 760,000 646,000 
Practice Collections(3)
$401.5 $339.9 $1,112.8 $949.0 
(1) Implemented Providers is defined as the total of all service professionals on Privia Health’s platform at the end of a given period who are credentialed by Privia Health and billed for medical services, in both Owned and Non-Owned Medical Groups during that period.
(2) Attributed Lives are defined as any patient that a payer deems attributed to Privia Health, in both Owned and Non-Owned Medical Groups, to deliver care as part of a Value Based Care arrangement. Attributed lives include patients who have selected one of Privia Health’s owned or Non-Owned Medical Groups as their provider of primary are services as of the end of a particular period.
(3) Practice Collections are defined as the total collections from all practices in all markets and all sources of reimbursement that the Company receives for delivering care and providing Privia Health’s platform and associated services. Practice Collections differ from revenue by including collections from Non-Owned Medical Groups.
(a) Any slight variations in totals are due to rounding.

Non-GAAP Financial Measures (4)(a)
For the Three Months Ended September 30,For the Nine Months Ended September 30,
(unaudited; $ in thousands)2021202020212020
Care Margin$61,469$46,738$169,782$136,317
Platform Contribution31,10221,49779,76259,184
Platform Contribution Margin50.6%46.0%47.0%43.4%
Adjusted EBITDA13,8679,13133,85123,202
Adjusted EBITDA Margin22.6%19.5%19.9%17.0%
(4) In addition to results reported in accordance with GAAP, Privia Health discloses Care Margin, Platform Contribution, Platform Contribution margin, Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. Each are defined as follows:
Care Margin is total revenue less the sum of physician and practice expense.
Platform Contribution is total revenue less the sum of (i) physician and practice expense, (ii) cost of platform, and (iii) stock-based compensation expense included in the cost of platform.
Platform Contribution margin is platform contribution divided by care margin.
Adjusted EBITDA is net income (loss) attributable to Privia Health Group, Inc. shareholders and subsidiaries excluding minority interests, provision (benefit) for income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation, severance charges and other nonrecurring expenses.
Adjusted EBITDA margin is Adjusted EBITDA divided by Care Margin.
(a) Any slight variations in totals are due to rounding.

9


Reconciliation of Operating (Loss) Income to Care Margin(a)
For the Three Months Ended September 30,For the Nine Months Ended September 30,
(unaudited; $ in thousands)2021202020212020
Operating (loss) income $(12,809)$8,543$(198,089)$21,218
Depreciation and amortization 4664571,3511,389
General and administrative 33,9109,788216,56329,196
Sales and marketing 4,5882,70918,9507,381
Cost of platform 35,31425,241131,00777,133
Care margin $61,469$46,738$169,782$136,317
(a) Any slight variations in totals are due to rounding.
Reconciliation of Operating (Loss) Income to Platform Contribution(a)
For the Three Months Ended September 30,For the Nine Months Ended September 30,
(unaudited; $ in thousands)2021202020212020
Operating (loss) income$(12,809)$8,543$(198,089)$21,218
Depreciation and amortization 4664571,3511,389
General and administrative 33,9109,788216,56329,196
Sales and marketing 4,5882,70918,9507,381
Stock-based compensation(5)
4,94740,987
Platform contribution $31,102$21,497$79,762$59,184
(a) Slight variations in totals are due to rounding.
(5) Amount represents stock-based compensation expense included under Cost of Platform.

Reconciliation of Net (Loss) Income to Adjusted EBITDA(a)
For the Three Months Ended September 30,For the Nine Months Ended September 30,
(unaudited; $ in thousands)2021202020212020
Net (loss) income$(9,115)$16,685$(176,251)$27,380
Net loss attributable to non-controlling interests(1,776)(85)(2,509)(255)
Benefit from income taxes(2,210)(8,561)(20,214)(7,387)
Interest expense2925048851,480
Depreciation and amortization4664571,3511,389
Stock-based compensation25,800121228,461363
Other expenses(6)
410102,128232
Adjusted EBITDA$13,867$9,131$33,851$23,202
(a) Any slight variations in totals are due to rounding.
(6) Other expenses include certain non-cash or non-recurring costs.


10


Reconciliation of Net (Loss) Income to Adjusted Net Income and Adjusted Net Income Per Share(a)

For the Three Months Ended September 30,For the Nine Months Ended September 30,
(unaudited; $ in thousands)2021202020212020
Net (loss) income $(9,115)$16,685$(176,251)$27,380
Stock-based compensation25,800121228,461363
Intangible amortization expense162162482483
Benefit from income tax(2,210)(8,561)(20,214)(7,387)
Other expenses410102,128232
Adjusted net income attributable to Privia Health Group, Inc.
$15,047$8,417$34,606$21,071
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic $0.14$0.09$0.34$0.22
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted$0.13$0.09$0.31$0.22
Weighted average common shares outstanding – basic 105,896,62295,950,929101,576,77595,945,804
Weighted average common shares outstanding – diluted120,234,28695,950,929112,702,73095,945,804
(a) Any slight variations in totals due to rounding.


11
EX-101.SCH 3 prva-20211108.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 prva-20211108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Ex Transition Period Entity Ex Transition Period Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 prva-20211108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 privialogoa.jpg begin 644 privialogoa.jpg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end XML 7 prva-20211108_htm.xml IDEA: XBRL DOCUMENT 0001759655 2021-11-08 2021-11-08 0001759655 false 8-K 2021-11-08 Privia Health Group, Inc. DE 001-40365 81-3599420 950 N. Glebe Rd., Suite 700 Arlington, VA 22203 571 366-8850 false false false false Common Stock, $0.01 par value per share PRVA NASDAQ true false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 08, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 08, 2021
Entity Registrant Name Privia Health Group, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40365
Entity Tax Identification Number 81-3599420
Entity Address, Address Line One 950 N. Glebe Rd.,
Entity Address, Address Line Two Suite 700
Entity Address, State or Province VA
Entity Address, City or Town Arlington,
Entity Address, Postal Zip Code 22203
City Area Code 571
Local Phone Number 366-8850
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol PRVA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001759655
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://priviahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports prva-20211108.htm ex-9913q21earningrelease.htm prva-20211108.xsd prva-20211108_lab.xml prva-20211108_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "prva-20211108.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "prva-20211108.htm" ] }, "labelLink": { "local": [ "prva-20211108_lab.xml" ] }, "presentationLink": { "local": [ "prva-20211108_pre.xml" ] }, "schema": { "local": [ "prva-20211108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "prva", "nsuri": "http://priviahealth.com/20211108", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prva-20211108.htm", "contextRef": "i5fe5f4f50f504a148f9ebd4d582041c6_D20211108-20211108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://priviahealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "prva-20211108.htm", "contextRef": "i5fe5f4f50f504a148f9ebd4d582041c6_D20211108-20211108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://priviahealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001759655-21-000033-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001759655-21-000033-xbrl.zip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end